NCT00606359View on ClinicalTrials.gov

Immunogenicity of the Inactivated Split-Virion Influenza Vaccine in Renal Transplant Subjects

PHASE2CompletedINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

February 29, 2008

Study Completion Date

June 30, 2008

Conditions
InfluenzaOrthomyxoviridae Infections
Interventions
BIOLOGICAL

Inactivated, split-virion influenza virus

0.1 mL, Intradermal. 2 vaccinations 12 months apart

BIOLOGICAL

Inactivated, split-virion influenza virus

0.5 mL, Intramuscular. 2 vaccinations, 12 months apart

Trial Locations (1)

Unknown

Lyon

All Listed Sponsors
lead

Sanofi Pasteur, a Sanofi Company

INDUSTRY

NCT00606359 - Immunogenicity of the Inactivated Split-Virion Influenza Vaccine in Renal Transplant Subjects | Biotech Hunter | Biotech Hunter